OncoImmune announced data from its Phase IIa clinical trial of CD24Fc will be presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Meeting, taking place in Orlando, Florida in February. The Phase IIa data will be presented by the study’s Principle Investigator, Dr. John Magenau of the University of Michigan’s Department of Medicine, at 11:15 am on February 21. Dr. Pan Zheng, the Chief Medical Officer of OncoImmune, Inc., will present Phase III clinical trial design in a poster session on February 19-20th.
The Phase IIa study is a randomized, double blind, placebo controlled, multi-center study to investigate adding CD24Fc to standard of care tacrolimus and methotrexate in acute graft-versus host disease (GVHD) prophylaxis for allogeneic hematopoietic stem cell transplantation (HCT) with matched unrelated donors in treatment of leukemia and myelodysplastic syndrome. The trial included three CD24Fc dose cohorts: 240 mg at day -1, 480 mg at day -1, and the multi-dose cohort of 480-240-240 mg at day -1, day 14 and day 28.
The presentation, entitled, “Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus Host Disease,” outlines the safety and efficacy data of CD24Fc when used in combination with standard of care GVHD prophylaxis compared to placebo and historical controls. The results demonstrate that CD24Fc was safe and well tolerated in the patient population. Patients receiving CD24Fc performed significantly better than placebo and historical controls in 180 day grade III-IV GVHD-free survival, the planned primary endpoint for the Phase III trial. These data thus provided strong support for the primary endpoint and dosing regimen of the upcoming phase III clinical trial. In addition, significantly better relapse free survival (RFS) was observed over placebo control and historical controls. Overall survival (OS) was also significantly improved when compared with a matched historical control. Moreover, a significant, dose-dependent reduction of mucositis was observed.
CD24Fc is a first-in class fusion protein that selectively represses inflammation induced by tissue injury while preserving innate immune response to pathogens.
CD24Fc has received orphan drug designation from both the US FDA and European Medical Agency (EMA) for GVHD prophylaxis.
Graft-versus-host disease (GVHD) is a life-threatening condition that occurs when the immune competent cells in a tissue graft mount an immune attack against the host. GVHD is commonly associated with hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies. Activated donor T cells attack host epithelial cells following an inflammatory cascade that begins with the preparative myeloablative regimen.